Oncogenic and drug-sensitive ERBB2 mutations in GBM

大家都知道我拖時間，常愛抱佛腳的那型。所以我拖到下午兩點才開始寫，寫完拿著熱騰騰的文章給海蒂改。
如下:
ErbB2 is one member of the epidermal growth factor receptor family of receptor tyrosine kinases, which in humans includes HER1 (EGFR, ERBB1), HER2 (ERBB2), HER3 (ERBB3) and HER4 (ERBB4). ErbB receptors are essential mediators of cell proliferation and differentiation in the developing embryo and in adult tissues.

Overexpression of ERBB2 is found in 20-30% of human breast cancer, and ErbB2 activating tyrosine kinase mutations are also found in 4% of lung cancer. Target therapies, such as Herceptin/Lapatinib and Iressa/Tarceva, have proven therapeutic opportunities for the patients in breast cancer and lung cancer. A recent study from TCGA (The Cancer Genome Atlas) reported that there are 11 novel ERBB2 mutations found in GBM patient samples. Interestingly, 8/11 mutation cluster in extracellular domain II which immediate receptor-dimerization.

We demonstrate that a subset of ERBB2 mutations are oncogenic and are sensitive to small molecule inhibitors of enzymatic activity by using the NIH-3T3 soft agar assay. Although the frequency of these mutations is about 8% among GBM patients, our singular works indicate that it is important that several ERBB2 inhibitors might be effective for the GBM patients carrying ERBB2 mutations. More recently, FGFR3 mutations have also been identified in GBM patients. We have similarly shown the subset of the mutations are oncogenic and also sensitive to small molecular inhibitors.

看不懂沒關係，我懶得翻譯。